Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. *Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.*

¹ Univariate Analysis of Marketing Fees and its Impact on Medical ² Scheme Performance, South Africa

Michael Mncedisi Willie

Received: 11 February 2021 Accepted: 5 March 2021 Published: 15 March 2021

6 Abstract

3

4

Background: Marketing strategies are viewed as an investment in many corporate entities, 7 often used as tools to maximise shareholders' returns. Objectives: The study aimed to assess 8 the extent to which certain factors affected marketing activities and expenditure impact 9 scheme performance. Methods: The study entailed a univariate analysis of factors that affect 10 marketing activities and expenditure and their impact on scheme performance. The review 11 period of the study was the 2019 expenditure data reported by medical schemes in South 12 Africa. Results: The results indicated that restricted schemes spent significantly less on 13 marketing than open medical schemes in 2019. Similarly, very large and large schemes spend 14 more on marketing fees compared to medium and small. The number of benefit options also 15 attracted a higher marketing expense for medical schemes, with more than four benefit 16 options attracting more elevated levels of marketing fees. 17

18

Index terms— marketing fees, marketing initiatives, organisational performance, medical schemes, South
 Africa.

21 **1** Introduction

arketing strategies are investment strategies in many corporate entities that are used to maximise shareholders' 22 returns ?? Jemaiyo, 2013; Daniel, 2018). Various studies have shown the effect of poor marketing strategies on 23 organisational performance. According to Rodriguez et al., some companies have failed to increase their sales 24 25 revenue due to poor marketing strategies ??Rodriguez et al., 2012). Various studies have cited poor marketing as one of the contributing factors to business failure, particularly small and medium enterprises (Petrus, 2009; 26 Nemaenzhe, 2010; Gbolagade et al., 2013). Owomoyela et al. argued that marketing strategies should provide 27 customers with quality products at an affordable price, offer effective promotional strategies, interact with their 28 distribution outlets, and ultimately create value for the customer and increase performance ??Owomovela et al., 29 2013). M II. 30

31 2 Background

Medical scheme membership is a proxy for assessing medical scheme performance in terms of enrolment into the schemes. An increase in membership is a function of new enrollees joining the scheme; this implies higher contribution income levels and thus higher revenue for the scheme (Ambler, 2003). Membership in medical schemes has stagnated at the level of 8 million for the past decade (C.M.S., 2019). Non-health care costs, including marketing and distribution costs, have been increasing and outstripping the rate of growth in the sector.

A study conducted by Willie et al. showed that an increase in marketing fees is not always a function of membership ??Willie et al., 2020). Studies have shown that poor marketing strategies are one of the attributes contributing to poor organisational performance. Rodriguez et al. ??2012) noted that most companies failed to increase their sales revenue due to poor marketing strategies. Studies have shown that poor marketing strategies can potentially lead to poor organisational performance. However, marketing programs expenditure and its impact on organisational performance has not been investigated widely, in particular for non-for-profit organisations (Daniel, 2018).

45 **3 III.**

⁴⁶ 4 Literature Review a) Marketing performance measures

Various quantitative measurements of marketing effectiveness include return-on-investment (R.O.I.). Chanand 47 colleagues employed a portfolio analysis approach to assess the association between marketing fees and the 48 market value of firms (Baidya & Basu, 2008). The study could not find any relationship between marketing fees 49 and the market value of organisations. However, Konak found an association between marketing fees and firm 50 performance (Konak, 2015; ??'Sullivan et al., 2009). This study, therefore, tested the effects of medical scheme 51 expenditure on marketing activities (advertising, sales classified as brokerage fees, promotion, distribution) and 52 their effect on organisational performance (improved financial performance measured by solvency levels). The 53 study investigated sales and marketing fees over time. The author presented the monthly financial income 54 statement for each respective brand over the study period. The authors found that the nature of the significant 55 relationship between distribution costs and sales was positive. However, another body of evidence suggested that 56 product development does not necessarily translate to firm performance. 57

A study by ??wokah et al. (2009) assessed the relationship between product size and other factors such as product design and profitability, sales volume and customer loyalty and showed that it was not significant ??Nwokah et al., 2009). According to Pleshko and Heiens, the relationship between product-market strategies and individual firm growth is incompletely understood ??Pleshko & Heiens, 2008). The average number of products offering in medical schemes is three (3). However, this varies according to medical schemes type and size. Only a handful of studies looked at product offering and expenditure on marketing activities (Mizik & Nissim, 2011).

⁶⁵ 5 c) Advertising

Advertising has also been depicted as the most widely researched variable of the promotional mix (Saif,
 2018). According to Esteve-Pérez and Mañez-Castillejo, organisations that develop firm-specific assets through
 advertising and investing in research and development (R&D) had more success in surviving (Esteve-Pérez &

Mañez-Castillejo, 2008). According to Frolova, advertising increased sales and a product's life cycle (Frolova,

⁷⁰ 2014). A recent study by Rahman et al. examined the effect of advertising productivity on firm performance

(Rahman et al., 2020). The study provided evidence of advertising efficiency and profitability in the health care
 sector. The study showed that advertising efficiency does vary between firms and that the higher the level of

r3 efficiency, the better the firm's profitability level can become.

The authors provided a body of evidence with mixed results on the effect of advertising on firm performance

75 ??Rahman et al., 2020). According to the authors, no study thus far has investigated whether or how advertising 76 efficiency impacts firm performance, distinct from how the absolute amount of advertising expenditure impacts

77 firm performance. ??Rahman et al., 2020). The researcher assessed whether the amount of money spent on

78 advertising affected a firm's financial performance.

⁷⁹ 6 d) Marketing distribution

The distribution channel is an essential component of the marketing strategy mix (Saif, 2018; Lamberti & Noci, 2010). Distribution expenses are all expenses incurred to improve the product reach from the manufacturer to the end-user. A study by Adimo and Osodo (2017) investigated the impact of distribution channel differentiation on organisational performance. Another study by Amara studied the effect of marketing distribution channel strategies on a firm's performance among commercial banks in Kenya (Amara, 2012). The author found that marketing distribution strategies resulted in increased sales, market share and profits.

⁸⁶ 7 e) Sector and firm size

Zehir and Balak examined the effects of sectoral differences and market dynamism and the relationship between the importance of metrics and firm performance (Zehir & Balak, 2018). According to O'Sullivan and Abela, product size is correlated with profitability and sales volume (O'Sullivan & Abela, 2007). The authors measured the ability of marketing performance and its impact on firm performance within a firm. The authors controlled firm size and firm age and measured their effect on firms' performance (O'Sullivan & Abela, 2007). Another study by Gitundu et al., found that firm size (log of assets) was correlated to share, ROA and Tobin's Q (Gitundu et

93 al., 2016).

⁹⁴ 8 f) Business operating model

The operating model and other structural factors have various dynamics to firm performance and its survival. Saleh argued that organisational structural elements should affect performance outcomes (Saleh, 2015; Gitahi & K'Obonyo, 2018). The author further argued that the ability of a firm to manage resources best would affect its performance levels. Marketing capability was also studied from a resource-based perspective and showed its essential impact on operations' capacity (Bromiley & Rau, 2016;Krasnikov & Jayachandran, 2008). Operations' capacity was positively linked to a firm's efficiency (Kamboja et al., 2015;Bromiley & Rau, 2016). A study by ??amboja et al. provided a new viewpoint to model the functional capabilities of firms (Kamboja et al., 2015). The authors emphasised that a firm with strong marketing capabilities leads to superior financial performance than those focusing solely on operational capabilities (Kamboja et al., 2015). The study found that both marketing and operations have capabilities to be significantly linked to and positively influence financial performance. There is, however, a body of knowledge that depicts a minor association between organisational, functional dimension and performance.

Yu and Ramanathan argued that previous studies had paid little attention to mediation analysis when examining the relationship between operational capabilities and performance (Yu & Ramanathan, 2016). This study also looked at the effect of marketing capabilities from the operating model. a stratification of internal versus external or outsourced model was assessed to assess the optimal use of resources.

¹¹¹ 9 g) Market share

Market share, considered an antecedent of cash flow and profitability, is another metric frequently used by 112 scholars and practitioners (Hacioglu & Gök, 2013) However, another body of knowledge argued against the use 113 of market share as a measure of performance by alleging that marketing activities do not always translate to 114 O.P. Inconsistent findings and different explanations on the effect of market share on firm performance suggested 115 further research in this vital area (Yannopoulos, 2010). The author found market share to contribute to higher 116 profitability, although it may have been exaggerated in the past (Yannopoulos, 2010). This depicts a further 117 need to assess the effect of market share as one of the market performance measures and their association with 118 firm performance, particularly in the health care market. 119

120 IV.

121 10 Objectives

The study's objective was to assess to what extent factors that affect marketing activities and expenditure impacted scheme performance.

124 V.

¹²⁵ 11 Methods a) Study design

The study entailed a univariate analysis of factors that affect marketing activities and expenditure and their impact on scheme performance. More precisely, an analysis of variance (ANOVA) was employed to compare marketing fees. A Chi-square test was conducted to compare marketing performance to scheme performance (mainly market share and financial performance). Market share measured by growth in customer base, profit ratio, sales growth, and customer satisfaction were also considered some of the determinants of organisational performance (Chin et al., 2013). For this research scheme, performance was assessed from a financial perspective, chiefly being:

- 133 ? Increase in market share in terms of membership.
- $_{\rm 134}$ $\,$? Financial performance such as profits and deficits.
- The study mainly used secondary data collected from the Council for Medical Schemes (C.M.S.) annual report. The review period of the study claimed and audited transaction or claims information in 2019.

¹³⁷ 12 b) Population and sample i. Population

A population is defined as the entire set of subjects whose characteristics are of interest in the research. Alvi established a target population, saying that "a target population refers to all the members who meet the criteria specified for a research investigation" (Alvi, 2016). The population in this study was drawn from the medical scheme's expenditure data.

142 13 iii. Setting

Medical schemes, also called health insurance companies operating in the private health sector in South Africa, are non-for-profit entities governed by a board of trustees and must be registered with the Council for Medical Schemes (C.M.S.). The C.M.S. is a statutory body, a section 31 entity that regulates medical schemes in South Africa. There are two types of medical schemes: namely open and restricted medical schemes. Open membership schemes must accept anyone who wants to become a member (Medical Schemes Act 131 of 1998). Restricted

¹⁴⁷ schemes must accept anyone who wants to become a member (Medical Schemes Act 131 of 1998). Restricted ¹⁴⁸ membership schemes can restrict who may become members, and they are typically employer or union-based

(Medical Schemes Act 131 of 1998). Schemes were further stratified by size, and the following stratifications were

150 employed:

151 ? Small < 6 000 members Univariate Analysis of Marketing Fees and its Impact on Medical Scheme 152 Performance, South Africa

¹⁵³ 14 ii. Sampling and sampling method

This study employed a convenient sampling frame, a non-probabilistic sampling method (Elfil & Negida, 2017; Wretman, 2010). The participants in a convenience sampling frame are consecutively selected in order of appearance, according to their convenient accessibility (also known as consecutive sampling) (Martínez-Mesa
et al., 2016). This method is quick, inexpensive, and convenient, and the sample elements are chosen according
to their convenient accessibility and proximity (Singh & Masuku, 2014). The study included a total of 54 medical
schemes (12 open and 42 restricted schemes). The number of beneficiaries and marketing fees in 2019 was 68%,
and 65% of industry, respectively.

Volume XXI Issue III Version I Year 2021 () E@ 2021 Global Journals

? Medium => 6 000 members but < 30 000 beneficiaries ? Large => 30 000 beneficiaries iv. Unit of measures The unit of measurement for expenditure data was in rand terms (R: ZAR). This was further adjusted for membership for comparison purposes, and this was denoted by "B.M.". As of 20 May 2020, the equivalent value was:? 1 ZAR to GBP = 0.0502 ? 1 ZAR = 0.07077 USD VI.

166 15 Results

167 The analysis included a total of 54 medical schemes, which was a convenience sampling frame.

The number of beneficiaries and marketing fees accounted for 68% and 65% of the industry beneficiaries and the marketing fees.

¹⁷⁰ 16 a) Sector or scheme type effect

The results indicated that restricted schemes spent significantly less on marketing compared to open medical schemes in 2019, with a median (IQR) of R12.7 (R9.3-R20.6) compared to R160 (R68.2-R200.2), F-value=16.43, p-value=0.0002.

174 **17** a. Size effect

175 Similarly, very large and large schemes spend more on marketing fees compared to medium and small schemes,

¹⁷⁶ with the median being(IQR), R173.8 (R65.0-R239.0); R142.4 (R91.3-R342.7), compared to R14.4 (R9.5-R80.7)

and R13.4 (R9.9-R18.3), respectively. These were statistically significant, F-value=7.82, p=0.0003.

178 18 b. Product line effect

The number of benefit options also attracted a higher marketing expense for medical schemes with more than four 179 benefit options attracting more high marketing fees than schemes with only two benefit options, with the median of 180 R160.2 (R95.1-R239.0) and R12.4 (R10.5-R91.3). Schemes with only one benefit option attracted marketing much 181 lower expense, compared to schemes with three or four benefit options, R10.0 (R6.1-R15.9) and R13.9 (R12.5-182 R26.6) or R15.74 (R7.6-R24.7), respectively. These comparisons were also statistically significant, F-value=7.7, 183 p=0.0001. The business operating model was also a critical factor in marketing expense. Schedules with an 184 insourced operating model (n=8) spend more on marketing activities than those with an outsourced business 185 operating model (n=46). The median expense of R125.9 (R91.3-R177.9) and R14.0 (R9.5-R80.7). These were also 186 statistically significant, F-value=4.9, p=0.0323. Lastly, marketing performance was not statistically significant 187 188 compared to organisational performance (market share) and financial performance, Chi-square=, p=0.99; and Chi-square=0.51, p=0.47. Figure ??: A box and whisker plot for marketing fees adjusted for membership by 189 type of business operating model. 190

¹⁹¹ 19 d. Marketing performance

Figure ?? below depicts a box and whisker plot for marketing fees adjusted for membership and by marketing 192 performance (Positive depicts an increase in marketing fees while negative depicts a decrease in marketing 193 fees compared to the previous year. The results show that medical schemes that experienced an increase in 194 their marketing fees between 2018 and 2019 paid slightly less than those that experienced a decrease. The 195 respective median expenditure was R14.3 (R10.5-R128.6) and R20.2 (R5.3-R109.5). These were however not 196 statistically significant, F-value=0.0, p=0.99. Figure ??: A box and whisker plot for marketing fees adjusted 197 for membership and by marketing performance (Positive depicts an increase in marketing fees wholes Negative 198 represents decreased marketing fees compared to the previous year). 199

200 Figure 6 below depicts a box and whisker plot for marketing fees, adjusted for membership and financial 201 performance measured by net surplus/ (deficit) after consolidation results. A positive category depicts an increase 202 in the net surplus, while a decrease describes a decline or loss. The results show that medical schemes that 203 experienced a positive financial performance spent twice as much as those that shared reductions or losses. The respective median expenditure was R21.5 (R10.0-R109.5) and R13.9 (R6.1-R142.4). These were, however, not 204 statistically significant, F-value=0.5, p=0.4799. This study also sought to test whether there was a relationship 205 between marketing fees and organisational performance. The findings depicted that marketing performance was 206 not statistically significant compared to organisational performance (market share or change in membership) and 207 financial performance, Chi-square=, p=0.99; and Chi-square=0.51, p=0.47. 208

209 **20 VII.**

210 21 Discussion

This study assessed to what extent factors affect marketing activities and expenditure impact on scheme 211 performance. The variables' associations were evaluated using a Chi-square test for groups with two variables and 212 ANOVA for groups with more than two variables. The study's marketing fees varied by sector and it was found 213 to be higher in open schemes than in restricted schemes-further depicting varied characteristics and showing 214 the effect of sector characteristics on marketing fees. The literature described sectoral differences and market 215 dynamism and their relationship and importance to firms' performance ???Zehir & Balak, 2018). The study 216 showed that marketing fees adjusted for membership was significantly higher for open schemes than for restricted 217 schemes. This was consistent with sector characteristics. According to Bizcommunity, Public or 'open' medical 218 schemes aggressively market themselves compared to large organisations with restricted membership schemes 219 (Bizcommunity, 2017). Restricted schemes are not allowed to market themselves. Thus, marketing fees incurred 220 in this sector are worrying and should be further interrogated. A study by Zehir and Balak examined the effects 221 of sectoral differences and market dynamism and the relationship between the importance of metrics and firms' 222 223 performance ??Zehir & Balak, 2018).

This study found that the business operating model influenced marketing fees, emphasising the importance of investing in internal resources. The literature depicted the effect of the business operating model on performance. Kamboja et al. showed that marketing capabilities impact superior financial performance (Kamboja et al., 2015). Secondly, the study found higher expenditure levels in large and very large schemes than medium and small medical schemes, further illustrating the size factor. The study also found product development impact on marketing fees in that an increased number of products offered attracts higher marketing fees.

The study found that marketing fees in higher expenditure levels occurred in medical schemes with more than 230 four benefit options. This finding depicts the effect of product design, product line and derivatives and potential 231 marketing fees associated with the much more comprehensive range. According to O'Sullivan and Abela (2007), 232 product size is correlated with profitability, sales volume. However, many products often have higher marketing 233 and distribution fees, which does not always translate to improved organisational performance. Several studies 234 have demonstrated this phenomenon. A study by Nwokah et al. assessed the relationship between product size 235 and other factors such as product design and profitability, sales volume and customer loyalty were not significant 236 237 ??Nwokah et al., 2009).

According to Pleshko and Heiens, the relationship between product-market strategies and individual firm growth is incompletely understood ??Pleshko & Heiens, 2008). In conclusion, this study found some evidence of critical factors that impact marketing fees. However, these were determinants of organisational performance, both in market share and financial performance. The findings of this study are in contrast with some of the other literature. Chan et al. employed a portfolio analysis approach to assess the association between marketing fees and the market value of firms (Baidya & Basu, 2008). The study could not find any relationship between marketing fees and the market value of organisations, which is consistent with the findings of this study.

Konak found a relationship between marketing fees and firm performance (Konak, 2015; ??'Sullivan et al.,
2009). Thus, depicting that investment programs and marketing programs and expense associated strategies
should maximise shareholders' returns (Jemaiyo, 2013). Therefore, further assessment of marketing initiatives in

$_{248}$ 22 Conclusion

The findings of the univariate analysis depicted that factors such as the sector that the medical scheme operates in (open schemes compared to restricted schemes) affect marketing fees. Secondly, the study found higher spending levels in large and very large schemes than in medium and small types of medical schemes. The study also found product development factors to be one of the explanatory factors of marketing fees, where higher expenditure levels were found in medical schemes with more products.

254 **23** IX.

255 24 Limitations

The following items have been identified as research limitations: a. This study will only consider the transaction 256 data as a marketing audit approach to determine the quality and effectiveness of the marketing inputs (Gao, 2010 257 ??Gao, , 2002 strategies employed in the healthcare market could provide better insights into the key drivers of 258 259 marketing initiatives expenditure and their impact on growth strategies. A study by Chendall and Langfield-260 Smith found that marketing management plays an essential role in assessing the effectiveness and efficiency of 261 marketing decisions (Chendall & Langfield-Smith, 2007). The importance of management perspective was also 262 depicted by O'Sullivan et al., who in their study included senior marketing managers to examine the effect of the ability to measure marketing performance on firms' performance (O'Sullivan et al., 2009). c. Member's 263 perspective could not be explored due to the researcher's limited access to member contact information. Member's 264 perspective is essential when trying to measure the value of marketing initiatives. Thus, both financial and 265 otherwise, resources and investments should be viewed as a value add to members (Doyle, 2000). According 266 to Terblanche et al., marketing investments and strategies were evaluated based on their ability to enhance 267

value (Terblanche et al., 2013). d. The marketing function is outsourced in some schemes, while others have
marketing initiatives as an in-house function. Thus, the performance of the marketing activity, in some instances,
is a function of third-party performance. e. The reporting of marketing fees by schemes is not consistent across
schemes. f. Organisation performance was evaluated from the financial perspective rather than from non-financial
measures. The non-financial key indicators typically would include customer satisfaction measures (Shavazi et al., 2013).

1

274 25 Conflict of interests

The author declared that no competing interests existed in the completion of this research.



Figure 1: Figure 1 :

275

 $^{^{1}}$ © 2021 Global Journals



Figure 2: Figure 2 :



Figure 3: Figure 3 :



Figure 4: Figure 6 :



Figure 5:

Figure 6:

1

financial performance) N (%)

Chi-square, p

Figure 7: Table 1 :

Figure 8:

276 .1 Authors contributions

277 The author drafted and proofread the article.

²⁷⁸.2 Global Journal of Management and

- 279 Business
- [Medical Schemes Act (1998)] , https://www.gov.za/sites/default/files/a131-98.pdf.
 Accessed Medical Schemes Act 1998. 1998. 18 July 2019. 131.
- 282 [Annual Report ()], Annual Report 2018/2019. Pretoria South Africa.
- [Alvi ()] A Manual for Selecting Sampling Techniques in Research, M H Alvi . 2016. Pakistan. University OF
 Karachi, Iqra University
- [Kamboja et al. ()] 'A resource-based view on marketing capability, operations capability and financial performance: An empirical examination of mediating role'. S Kamboja, P Goyal, Z Rahman. Procedia -Social and Behavioral Sciences 2015. 189 p.
- [Mizik and Nissim ()] Accounting for Marketing Activities: Implications for Marketing, N Mizik , D Nissim .
 2011.
- [Hosseini et al. ()] 'Competitive Advantage and Its Impact on New Product Development Strategy (Case
 Study: ToosNirro Technical Firm)'. A S Hosseini , S Soltani , M Mehdizadeh . http://jetems.
- scholarlinkresearch.com/ Journal of Emerging Trends in Economics & Management Sciences 2018.
 2013. 4 (3) p. . (Journal of Open Innovation)
- [Mbithi et al. ()] 'Effect of product development strategy on performance in the sugar industry in Kenya'. B
 Mbithi, W Muturi, C Rambo. International Journal of Academic Research in Business and Social Sciences
 2015. 5 (12) p. .
- [Baidya and Basu ()] 'Effectiveness of marketing feess: A brand level case study'. M Baidya , P Basu .
 10.1057/jt.2008.12. https://doi.org/10.1057/jt.2008.12 J Target Meas Anal Mark 2008. 16 p. .
- [Daniel ()] 'Effects of Marketing Strategies on Organizational Performance'. C O Daniel . International Journal
 of Business Marketing and Management 2018. 3 (9) p. .
- [Liu et al. ()] 'Effects of Product Development on Operating Performance in the Textile Industry'. C M Liu , K
 W Lin , C J Huang . Anthropologist 2014. 17 (1) p. .
- [Chirla and Funar ()] 'External marketing audit and internal marketing audit. Comparative study'. G Chirla , S
 Funar . Bulletin UASVM Horticulture 2010. 67 (2) p. .
- [Kaleka and Morgan ()] 'How marketing capabilities and current performance drive strategic intentions in
 international markets'. A Kaleka , N A Morgan . Industrial Marketing Management 2017. 2017. 78 p. .
- [Gbolagade et al. ()] 'Impact of Marketing Strategy on Business Performance a Study of Selected Small and
 Medium Enterprises (SMES) In Oluyole Local Government'. A Gbolagade , M A Adewale , I O Oyewale .
 Journal of Business and Management 2013. 11 (4) p. .
- ³¹⁰ [Chin et al. ()] 'Market orientation and organisational performance: The moderating role of service quality'. C ³¹¹ H Chin , M C Lo , T Ramayah . Sage Open 2013. 3 (4) p. 2158244013512664.
- [Hussain ()] 'Market orientation and performance: The interaction effect of entrepreneurial orientation'. Hussain
 Pakistan Journal of Commerce and Social Sciences (PJCSS) 2309-8619. 2016. Johar Education Society. 10
 (2) p. .
- [Ambler ()] Marketing and the bottom line: The marketing metrics to pump up cash flow, T Ambler . 2003.
 London, England: Financial Times Prentice Hall. (Second edition)
- [Lipnická and ?a?o ()] 'Marketing Audit and Factors Influencing Its Use in Practice of Companies (From an Expert Point of View)'. D Lipnická, J ?a?o. Journal of Competitiveness 2013. 5 (4) p. .
- [Hacioglu and Gök ()] 'Marketing performance measurement: marketing metrics in Turkish firms'. G Hacioglu ,
 O Gök . 10.3846/16111699.2012.729156. https://doi.org/10.3846/16111699.2012.729156 Journal
- of Business Economics and Management 2013. 14 (1) p. .
- [Lamberti and Noci ()] 'Marketing strategy and marketing performance measurement system: Exploring the
 relationship'. L Lamberti , G Noci . European Management Journal 2010. 28 (2) p. .
- [Gao ()] Measuring Marketing Performance: A Review and a Framework: The Marketing Review, Y Gao.
 10.1362/146934710X488924. 2010. 2010. 10 p. .
- 326 [Ambler and Kokkinaki ()] 'Measuring Marketing Performance: Which Way Is Up?'. T Ambler , F Kokkinaki
- Business Performance Measurement, A Neely (ed.) (Cambridge) 2002. 2002. 2002. Cambridge University
 Press. p. .
- 329 [Chendall and Langfield-Smith ()] 'Multiple perspectives of performance measures'. R H Chendall , K Langfield-
- 330 Smith . European Management Journal 2007. 25 (4) p. .

25 CONFLICT OF INTERESTS

- Bromiley and Rau ()] 'Operations management and the resource-based view: Another view'. P Bromiley , D
 Rau . 10.1016/j.jom.2015.11.003. Journal of Operations Management 2016. 41 p. .
- [Elfil and Negida ()] 'Sampling methods in Clinical Research; an Educational Review'. M Elfil , A Negida .
 Emergency 2017. 5 (1) p. e52.
- [Martínez-Mesa et al. ()] 'Sampling: how to select participants in my research study'. J Martínez-Mesa , D A
 González-Chica , R P Duquia , R R Bonamigo , J L Bastos . Anais brasileiros de dermatologia 2016. 91 (3)
 p. .
- 338 [Alsem ()] Strategic marketing: an applied perspective, K J Alsem . 2007. New York: McGraw-Hill.
- Bizcommunity ()] The case for a restricted medical scheme, Bizcommunity . https://www.bizcommunity. com/PDF/PDF.aspx?l=196&c=320&ct=1&ci=161045 2017.
- ³⁴¹ [Lo et al. ()] 'The critical success factors for the organisational performance of S.M.E.s in Malaysia: a partial
 ³⁴² least squares approach'. May Lo, Chiun, Yin Wang, Chai, Constance Rinen Wah, Justin, T Ramayah.
 ³⁴³ Revista Brasileira de Gestão de Negócios 2016. 18 (61) p. .
- [Amara ()] The Effect of Marketing Distribution Channel Strategies on a Firm's Performance among Commercial
 Banks in Kenya, S Amara . 2012. School of Business, University of Nairobi
- [Konak ()] 'The Effects of Marketing Expenses on Firm Performance: Empirical Evidence from the BIST Textile,
 Leather Index'. F Konak . Business and Management Journal of Economics Business and Management 2015.

348 3 p. . (Journal of Economics)

- [Adimo and Osodo ()] 'The impact of distribution channel differentiation on organisational performance: The
 case of Sameer Africa Limited in Nairobi'. A A Adimo , O P Osodo . Kenya. International Journal of Business
 and Management Review 2017. 5 (2) p. .
- [Gitahi and Obonyo ()] 'The Relationship between Organizational Resources and Firm Performance of Com panies Listed on the Nairobi Securities Exchange'. A W Gitahi , P O Obonyo . International Journal of
 Economics, Commerce and Management 2018. 6 (5) p. .
- [Krasnikov and Jayachandran ()] 'The Relative Impact of Marketing, Research-and-Development, and Operations Capabilities on Firm Performance'. A Krasnikov, S Jayachandran. Journal of Marketing 2008. 72 (4)
 p. .
- [Esteve-Pérez and Mañez-Castillejo ()] 'The Resource-Based Theory of the Firm and Firm Survival'. S Esteve Pérez , J A Mañez-Castillejo . Small Business Economics 2008. 30 p. .
- [Frolova (2014)] 'The role of Advertising in Promoting a Product'. S Frolova . https://www.theseus.fi/
 bitstream/handle/10024/80777/Frolova_Svetlana.pdf.Accessedon Journal of Centria Univer-
- sity of Applied Science. Available on 2014. May 2021.
- ³⁶³ [Doyle ()] 'Value-Based Marketing'. P Doyle . Journal of Strategic Marketing 2000. 8 (4) p. .